At a glance
ClinicalIndex Comparison Record- ✓Age 18 to 35 years old at screening
- ✓Diagnosis of acne vulgaris with at least 20 inflammatory lesions and maximum 100 non-inflammatory lesions (excluding nose)
- ✓Symmetric distribution of lesions: no more than twice as many lesions on one side compared to the other
- ✓Female of childbearing potential must use effective contraceptive method during study
- ✕Underlying disease or medical condition that might interfere with study interpretation or put subject at risk (e.g., other dermatological diseases, uncontrolled chronic or serious diseases)
- ✕Severe acne types: acne conglobata, acne fulminans, secondary acne, nodulo cystic acne, or acne requiring systemic treatment
- ✕Known or suspected allergies or sensitivities to study drug components
- ✕Male with beard or facial hair that would interfere with clinical evaluation
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of CD5024 1% in Acne Vulgaris
In Brief
A Phase 2 clinical trial evaluating CD5024 1% cream, CD5024 cream placebo, and 2 other interventions for Acne. Completed, enrolled 70 participants across 7 sites in 3 countries.
Detailed Summary
Exploratory, multi-center, randomised, investigator-blinded, vehicle controlled study using intra-individual comparison involving subjects with acne vulgaris on face to evaluate the efficacy of CD5024 1% cream over a 6-week treatment period compared to its vehicle.
Study Details
Timeline
Interventions
500 µL on half-face, five days a week during 6 weeks
500 µL on half-face, five days a week during 6 weeks
500 µL on half-face, five days a week during 6 weeks
500 µL on half-face, five days a week during 6 weeks